- Home
- Publications
- Publication Search
- Publication Details
Title
NK cell-based immunotherapy for malignant diseases
Authors
Keywords
-
Journal
Cellular & Molecular Immunology
Volume 10, Issue 3, Pages 230-252
Publisher
Springer Nature
Online
2013-04-22
DOI
10.1038/cmi.2013.10
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy
- (2014) Liat Binyamin et al. JOURNAL OF IMMUNOLOGY
- Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy
- (2012) Martha Luevano et al. Cellular & Molecular Immunology
- Single line or parallel lines: NK cell differentiation driven by T-bet and Eomes
- (2012) Xiaojun Jiang et al. Cellular & Molecular Immunology
- Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
- (2012) Natalia Lapteva et al. CYTOTHERAPY
- Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells
- (2012) Xuewen Deng et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
- (2012) Cecele J. Denman et al. PLoS One
- Natural killer cell lines in tumor immunotherapy
- (2012) Min Cheng et al. Frontiers of Medicine
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
- (2011) A. Curti et al. BLOOD
- Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands
- (2011) Beatriz Sanchez-Correa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Establishment, Characterization, and Successful Adaptive Therapy against Human Tumors of NKG Cell, a New Human NK Cell Line
- (2011) Min Cheng et al. CELL TRANSPLANTATION
- Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy
- (2011) Thanh-Nhan Nguyen-Pham et al. Cellular & Molecular Immunology
- HMBOX1 negatively regulates NK cell functions by suppressing the NKG2D/DAP10 signaling pathway
- (2011) Longyan Wu et al. Cellular & Molecular Immunology
- Bone marrow and the control of immunity
- (2011) Ende Zhao et al. Cellular & Molecular Immunology
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
- (2011) M. R. Parkhurst et al. CLINICAL CANCER RESEARCH
- Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity
- (2011) Kory L. Alderson et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting
- (2011) I. N. Buhtoiarov et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Noninvasive cell-tracking methods
- (2011) Moritz F. Kircher et al. Nature Reviews Clinical Oncology
- Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
- (2011) Jan Spanholtz et al. PLoS One
- Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation
- (2010) David A. Rizzieri et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The cell labeling efficacy, cytotoxicity and relaxivity of copper-activated MRI/PET imaging contrast agents
- (2010) Daksha Patel et al. BIOMATERIALS
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
- (2010) H. E. Kohrt et al. BLOOD
- Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study
- (2010) Shimon Slavin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
- (2010) Eleni G. Iliopoulou et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Monitoring of Natural Killer Cell Immunotherapy Using Noninvasive Imaging Modalities
- (2010) P. Jha et al. CANCER RESEARCH
- Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
- (2010) F. Navid et al. CURRENT CANCER DRUG TARGETS
- Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients
- (2010) Uwe Siegler et al. CYTOTHERAPY
- Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor
- (2010) Tolga Sutlu et al. CYTOTHERAPY
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
- (2010) Melissa A. Geller et al. CYTOTHERAPY
- Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity
- (2010) Caroline J Voskens et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- PET/MRI: Paving the Way for the Next Generation of Clinical Multimodality Imaging Applications
- (2010) B. J. Pichler et al. JOURNAL OF NUCLEAR MEDICINE
- Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia
- (2010) Linda S. Sorkin et al. PAIN
- High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy
- (2010) Jan Spanholtz et al. PLoS One
- Ex vivo expansion of natural killer cells with high cytotoxicity by K562 cells modified to co-express major histocompatibility complex class I chain-related protein A, 4-1BB ligand, and interleukin-15
- (2010) W. Gong et al. TISSUE ANTIGENS
- Pluripotent stem cell-derived natural killer cells for cancer therapy
- (2010) David A. Knorr et al. Translational Research
- Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells
- (2009) D. S. Kaufman BLOOD
- Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity
- (2009) P. S. Woll et al. BLOOD
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
- (2009) H. Fujisaki et al. CANCER RESEARCH
- Cancer immunotherapy
- (2009) Constantin N. Baxevanis et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia
- (2009) Andrea Velardi et al. CURRENT OPINION IN IMMUNOLOGY
- Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
- (2009) Maria Berg et al. CYTOTHERAPY
- Immunotherapy of cancer
- (2009) Hossein Borghaei et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma
- (2009) Brett H Yamane et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Application of tissue-specific NK and NKT cell activity for tumor immunotherapy
- (2009) Jeff J. Subleski et al. JOURNAL OF AUTOIMMUNITY
- Intratumoral But Not Systemic Delivery of CpG Oligodeoxynucleotide Augments the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Against B Cell Lymphoma
- (2009) David J. Betting et al. JOURNAL OF IMMUNOTHERAPY
- Natural killer cell-based immunotherapy in cancer: current insights and future prospects
- (2009) T. Sutlu et al. JOURNAL OF INTERNAL MEDICINE
- Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death
- (2009) C. Li et al. MOLECULAR CANCER THERAPEUTICS
- Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
- (2009) C. Sola et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The impact of Fc engineering on an anti-CD19 antibody: increased Fc receptor affinity enhances B-cell clearing in nonhuman primates
- (2008) J. Zalevsky et al. BLOOD
- NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
- (2008) Karl-Johan Malmberg et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation
- (2008) Cai Zhang et al. CYTOKINE
- Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL
- (2008) W. Jiang et al. CYTOTHERAPY
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
- Cell tracking with optical imaging
- (2008) Elizabeth J. Sutton et al. EUROPEAN RADIOLOGY
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
- NK cells and cancer immunosurveillance
- (2008) I Waldhauer et al. ONCOGENE
- NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation
- (2007) Loredana Ruggeri et al. BLOOD CELLS MOLECULES AND DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More